AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 274
- Registration Number
- NCT00819234
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
Study to Investigate Safety, Tolerability and PK Following Single and Multiple Ascending Doses of AZD7295 in Japanese
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2009-07-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT00818129
- Locations
- 🇯🇵
Research Site, Fukuoka-City, Fukuoka, Japan
Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2012-11-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT00817778
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
To Evaluate the Bioavailability of a Tablet of AZD1656
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2009-11-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 11
- Registration Number
- NCT00817505
- Locations
- 🇺🇸
Research site, San Antonio, Texas, United States
To Evaluate the Response to Glucagon During Hypoglycemia
- First Posted Date
- 2009-01-06
- Last Posted Date
- 2009-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT00817271
- Locations
- 🇺🇸
Research Site, Chula Vista, California, United States
Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome
- First Posted Date
- 2008-12-30
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 97
- Registration Number
- NCT00815659
- Locations
- 🇹🇷
Research site, Kocaeli, Umuttepe, Turkey
🇹🇷Research Site, Trabzon, Turkey
ATAC - Endometrial Sub-Protocol
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-12-24
- Last Posted Date
- 2009-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 285
- Registration Number
- NCT00814125
14473 - D9126C00001 Proof of Principle Study - Effect of AZD2066 on Transient Lower Esophageal Sphincter Relaxations
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT00813306
- Locations
- 🇳🇱
Research site, Amsterdam, Netherlands
Physician and Patient Perception of Adjustable Maintenance Dosing of Symbicort Turbuhaler
Completed
- Conditions
- Perception of Physicians & Patients of AMD
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 217
- Registration Number
- NCT00812682
Effect of Ketoconazole on Biliary Excretion of AZD0837
- First Posted Date
- 2008-12-22
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00812344
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
© Copyright 2025. All Rights Reserved by MedPath